Dublin, June 29, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Malignant Melanoma Drug Market & Clinical Pipeline Insight" drug pipelines to their offering.
Research and development of malignant melanoma therapeutics has gained lots of attention in past few decades due to rapidly increasing incidences. Large numbers of clinical trials have been instigated to find an effective therapeutics having high safety and efficacy levels. Various products are at different stages of clinical trials which would be introduced in coming years. Their safety and efficacy is prime concern because investigators are still trying to understand exact mechanism behind factors leading to the development of malignant melanoma.
For instance, signaling pathways are complex and intertwined making it difficult for investigators to rely on single approach to treat malignant melanoma. In coming years, it is expected that investigators would be able to identify these factors resulting in development of pharmacologically superior products offering higher safety and efficacy profiles.
Many innovative therapeutics are at various phases of clinical trials for malignant melanoma treatment. They are expected to generated statistically significant data encouraging pharmaceutical companies to proceed with higher levels of confidence. The long-term effect of these innovative therapeutics is under investigation, sufficiently high safety and efficacy data will make it easy to apply for marketing approval in different countries.
In few years, owing to rapidly developing clinical pipelines, innovative malignant melanoma therapeutics are expected to enter in global market leading to increase in their market size. Future commercial success of these novel products seems to be optimistic but their commercialization may take some years.
Global Malignant Melanoma Drug Market & Clinical Pipeline Insight Report Highlight:
- Global Malignant Melanoma Market Analysis
- Malignant Melanoma Drug Mechanism of Action
- Global Malignant Melanoma Clinical Pipeline By Company & Phase
- Global Malignant Melanoma Clinical Pipeline: 201 Drugs
- Majority Malignant Melanoma Drugs in Preclinical Phase: 63 Drugs
- Global Malignant Melanoma Marketed Drugs Clinical Insight
- Marketed Malignant Melanoma Drugs: 25 Drugs
Key Topics Covered:
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. Global Malignant Melanoma Drug Market Future Prospects
6. Global Malignant Melanoma Clinical Pipeline By Company & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Registered
7. Global Malignant Melanoma Marketed Drugs Clinical Insight
7.1 Talimogene Laherparepvec (IMLYGIC)
7.2 Nivolumab (Opdivo)
7.3 Temozolomide (Temodal & Temodar)
7.4 Peginterferon alfa-2b (Cylatron, Intron A Peg, PEG-Intron A, Pegatron, Pegintron, Pegtron & ViraferonPeg )
7.5 Pembrolizumab (Keytruda )
7.6 Vemurafenib
7.7 Ipilimumab (Yervoy)
7.8 Cobimetinib (Cotellic)
7.9 Trametinib (Mekinist)
7.10 Tc 99m Tilmanocept (Lymphoseek)
7.11 Dabrafenib (Tafinlar)
7.12 Aldesleukin (Chiron IL-2 & Proleukin)
7.13 Interferon alpha-2b (Intron A, Viraferon & Virtron)
7.14 Interferon-beta-1b - Toray/Daiichi Sankyo (Feron)
7.15 Melanoma Vaccine - AVAX Technologies (MVax)
7.16 Interferon alpha - Swedish Orphan Biovitrim (Multiferon)
7.17 Interferon alpha-2b - Beijing Kawin Technology
7.18 Virulizin (Virulizin)
7.19 Vemurafenib Companion Diagnostic - Roche/Plexxikon (cobas 4800 BRAF V600 Mutation Test)
7.20 Dabrafenib-Trametinib Companion Diagnostic - bioMerieux/ GlaxoSmithKline/Response Genetics (THxID-BRAF)
7.21 Interferon alpha-2b Biosimilar - Reliance Life Sciences (ReliFeron)
7.22 Technetium Tc 99m Sulfur Colloid Injection - Pharmalucence
7.23 Interferon alpha-2a (Roferon-A)
7.24 Fotemustine (Muforan, Muphoran, Mustoforan & Mustophoran)
7.25 Melanoma Vaccine - GlaxoSmithKline (Melacine)
8. Competitve Landscape
8.1 AB Science
8.2 Celgene Corporation (Abraxis BioScience)
8.3 Array BioPharma
8.4 AVAX Technologies
8.5 Biogen Idec
8.6 BioVex
8.7 Bristol-Myers Squibb
8.8 Enzon Pharmaceuticals
8.9 Eisai Co
8.10 Exelixis
8.11 GlaxoSmithKline
8.12 Lorus Therapeutics (Aptose Bioscience)
8.13 Medarex
8.14 Merck
8.15 Navidea Biopharmaceuticals
8.16 Novartis
8.17 Ono Pharmaceutical
8.18 Onyx Pharmaceuticals
8.19 Pfizer
8.20 Pharmalucence (Sun Pharmaceutical Industries Limited)
8.21 Plexxikon
8.22 QIAGEN
8.23 Roche
8.24 Reliance Life Sciences
8.25 Servier
8.26 TC BioPharm
8.27 Viragen
For more information visit http://www.researchandmarkets.com/research/mbq832/global_malignant